Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fully Automatic Ultrafiltration System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fully Automatic Ultrafiltration System market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Fully Automatic Ultrafiltration System was estimated to be worth US$ 212 million in 2025 and is projected to reach US$ 299 million, growing at a CAGR of 5.1% from 2026 to 2032.
A fully automated ultrafiltration system is an intelligent device that integrates a pump, ultrafiltration membrane assembly, sensors, control system, and software. It automates operations such as sample injection, cyclic concentration, dialysis, cleaning, and drainage. It utilizes the molecular weight cut-off (MWCO) principle to efficiently separate and concentrate macromolecules such as proteins, nucleic acids, and viruses. The system features real-time monitoring of flow, pressure, temperature, and volume, supports programmed operation, and data logging. It is widely used in biopharmaceuticals, vaccine production, life science research, and other fields, offering advantages such as ease of operation, excellent reproducibility, avoidance of human error, and suitability for large-scale processing.In 2024, the global production of fully automatic ultrafiltration systems will reach 6,513 units, with an average selling price of US,899 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6099003/fully-automatic-ultrafiltration-system
1. Industry Pain Points and the Shift Toward Automated Ultrafiltration
Biopharmaceutical manufacturing and life science research require efficient, reproducible concentration and purification of proteins, nucleic acids, and viruses. Manual ultrafiltration processes are labor-intensive, prone to operator variability, and lack real-time monitoring and data logging. Fully automatic ultrafiltration systems address this by integrating pumps, membrane assemblies, sensors, and control software to automate sample injection, concentration, dialysis, cleaning, and drainage. For bioprocess engineers and researchers, these systems provide automated protein concentration, consistent results, and regulatory compliance (data logging, audit trails). Applications include monoclonal antibody (mAb) production, vaccine manufacturing, and gene therapy vector concentration.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global fully automatic ultrafiltration system market was valued at US$ 212 million in 2025 and is projected to reach US$ 299 million by 2032, growing at a CAGR of 5.1%. In 2024, global production reached approximately 6,513 units with an average selling price of US$ 32,899 per unit. Market growth is driven by three factors: expansion of biopharmaceutical manufacturing (mAbs, vaccines, gene therapies), increasing adoption of automated bioprocessing (Industry 4.0), and demand for data integrity and regulatory compliance (FDA 21 CFR Part 11, GMP).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- mAb manufacturing expansion: Monoclonal antibody production (cancer, autoimmune diseases) requires ultrafiltration for concentration and buffer exchange. mAb segment grew 15% year-over-year.
- Vaccine production demand: mRNA and viral vector vaccines (COVID-19, RSV, influenza) drive demand for automated ultrafiltration for purification and concentration. Vaccine segment grew 20% in 2025.
- Single-use adoption: Single-use ultrafiltration systems (Cytiva, Alfa Laval, Formulatrix) gained 25% market share, reducing cleaning validation burden and cross-contamination risk.
- Chinese supplier expansion: Biolink, Lisure, JYSS Bio, CHANSE, LePure, H&E Co., Ltd, Alioth, and others increased production by 30% collectively, capturing share in domestic biopharma market.
4. Competitive Landscape and Key Suppliers
The market includes global bioprocessing leaders and Chinese specialists:
- Biolink (China), Lisure (China), Cytiva (US/Sweden – former GE Healthcare Life Sciences), JYSS Bio (China), CHANSE (China), LePure (China), H&E Co., Ltd (China), Alioth (China), Alfa Laval Inc (Sweden/US), WesTech (US), FILTEC (US), Formulatrix (US).
Competition centers on three axes: automation level (fully programmable vs. semi-automatic), membrane area (cm² to m² for scale-up), and data compliance (21 CFR Part 11, audit trails).
5. Segment-by-Segment Analysis: Type and Application
By Form Factor
- Desktop: Small-scale (50 mL – 5 L). For R&D, process development, small-batch production. Account for ~60% of unit volume.
- Floor-standing: Large-scale (5 L – 500 L+). For commercial manufacturing. Higher throughput, GMP-compliant. Account for ~40% of market value.
By Application
- Biopharmaceuticals: Largest segment (~60% of market). mAb concentration, vaccine purification, gene therapy vector concentration, protein formulation.
- Research and Experimental Services: (~25% of market). Academic labs, CROs, process development. Protein and nucleic acid concentration, buffer exchange.
- Food and Environmental Testing: (~10% of market). Concentration of pathogens, toxins, contaminants from food and water samples.
- Other: Diagnostic reagent preparation, industrial enzymes. ~5% of market.
User case – mAb concentration automation: A biopharmaceutical company manufacturing mAbs (10,000 L bioreactor) replaced manual ultrafiltration (4 operators, 6 hours) with fully automatic system (Cytiva, 1 operator, 3 hours). Automated system provided real-time flow, pressure, and conductivity monitoring, with data logging for batch records. Reproducibility improved: concentration factor CV reduced from 8% to 2%. Annual labor savings: US$ 200,000.
6. Exclusive Insight: Manufacturing – Ultrafiltration System Components and Automation
Fully automatic ultrafiltration systems integrate multiple components:
System Components:
| Component | Function | Key Specifications |
|---|---|---|
| Pump | Fluid circulation | Peristaltic (low shear) or diaphragm |
| Membrane cassette | Size-based separation | MWCO: 1-1000 kDa, material: PES, RC, cellulose |
| Pressure sensors | Monitor TMP (transmembrane pressure) | Range: 0-5 bar, accuracy ±0.05 bar |
| Flow sensor | Monitor feed/permeate flow | Ultrasonic or magnetic, ±2% accuracy |
| Conductivity sensor | Buffer exchange monitoring | Range: 0-200 mS/cm |
| Control software | Automation, data logging | 21 CFR Part 11 compliant |
Automated Operations:
- Concentration: Reduce volume by 10-100x, monitor permeate flow rate
- Diafiltration (buffer exchange) : Replace original buffer with new buffer (5-10 diavolumes)
- Cleaning-in-place (CIP) : Automated cleaning with NaOH, sanitization
- Data logging: Record all process parameters for batch release
Technical challenge: Maintaining low shear to prevent protein denaturation and aggregation. High shear denatures proteins, reducing yield. Premium systems (Cytiva, Alfa Laval) use:
- Low-shear peristaltic pumps (smooth flow, no impeller)
- Gradual pressure ramping (avoid sudden pressure spikes)
- Controlled recirculation rates (optimized for each membrane)
User case – Shear sensitivity study: A protein formulation study compared manual vs. automatic ultrafiltration (same membrane, same protein). Automatic system with low-shear pump and controlled ramping achieved 98% protein recovery vs. 89% for manual (operator-dependent pressure control). Aggregation (HPLC-SEC) reduced from 5% to 1%.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (35% share, CAGR 5%). US (Cytiva, Alfa Laval, WesTech, FILTEC, Formulatrix), Canada. Strong biopharma and research base.
- Asia-Pacific: Fastest-growing region (CAGR 6%). China (Biolink, Lisure, JYSS Bio, CHANSE, LePure, H&E, Alioth), India, South Korea. Biopharma capacity expansion driving demand.
- Europe: Second-largest (30% share, CAGR 4.5%). Sweden (Alfa Laval, Cytiva). Established biopharma manufacturing.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The fully automatic ultrafiltration system market is positioned for steady growth through 2032, driven by biopharmaceutical expansion, vaccine production, and automation demands. Stakeholders—from system manufacturers to bioprocess engineers—should prioritize data logging for regulatory compliance, single-use flow paths for contamination control, and low-shear design for protein integrity. By enabling automated protein concentration and membrane separation, fully automatic ultrafiltration systems are essential for modern bioprocessing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
